AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).

Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...

Ameritas Advisory Services LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 25.9% during the fourth quarter, according to the company in its most recent disclosure ...

ABU DHABI, 6th June, 2017 (WAM) -- The UAE Ministry of Health and Prevention has issued a circular to all medical facilities and hospitals to withdraw Brilinta 90 mg batch number JB504 by AstraZeneca, ...

May 2017 – Outcomes-based agreements with AstraZeneca for Brilinta (ticagrelor) and Bydurean (exenatide extended-release) to treat acute coronary disease and type II diabetes respectively.

A new investigation published by The BMJ highlights fresh concerns about the PLATO clinical trial, a pivotal study that led to the global approval of the anti-platelet drug ticagrelor (marketed as ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...